Back to Search
Start Over
Delivery of mengovirus-derived RNA replicons into tumoural liver enhances the anti-tumour efficacy of a peripheral peptide-based vaccine
Delivery of mengovirus-derived RNA replicons into tumoural liver enhances the anti-tumour efficacy of a peripheral peptide-based vaccine
- Source :
- Cancer Immunology, Immunotherapy, Cancer Immunology, Immunotherapy, Springer Verlag, 2008, 57 (8), pp.1161-71. ⟨10.1007/s00262-007-0448-3⟩, Cancer Immunology, Immunotherapy, 2008, 57 (8), pp.1161-71. ⟨10.1007/s00262-007-0448-3⟩, Cancer Immunology and Immunotherapy, Cancer Immunology and Immunotherapy, 2008, 57 (8), pp.1161-71. 〈10.1007/s00262-007-0448-3〉
- Publication Year :
- 2008
- Publisher :
- HAL CCSD, 2008.
-
Abstract
- International audience; Hepatocellular carcinoma is a deadly cancer with growing incidence for which immunotherapy is one of the most promising therapeutic approach. Peptide-based vaccines designed to induce strong, sustained CD8+ T cell responses are effective in animal models and cancer patients. We demonstrated the efficacy of curative peptide-based immunisation against a unique epitope of SV40 tumour antigen, through the induction of a strong CD8+ T cell-specific response, in our liver tumour model. However, as in human clinical trials, most tumour antigen epitopes did not induce a therapeutic effect, despite inducing strong CD8+ T cell responses. We therefore modified the tumour environment to enhance peptide-based vaccine efficacy by delivering mengovirus (MV)-derived RNA autoreplicating sequences (MV-RNA replicons) into the liver. The injection of replication-competent RNA replicons into the liver converted partial tumour regression into tumour eradication, whereas non-replicating RNA had no such effect. Replicating RNA replicon injection induced local recruitment of innate immunity effectors (NK and NKT) to the tumour and did not affect specific CD8+ T cell populations or other myelolymphoid subsets. The local delivery of such RNA replicons into tumour stroma is therefore a promising strategy complementary to the use of peripheral peptide-based vaccines for treating liver tumours.
- Subjects :
- Male
MESH : Prevalence
MESH: Immunotherapy
medicine.medical_treatment
MESH: Flow Cytometry
Epitope
MESH: Cancer Vaccines
Mice
0302 clinical medicine
MESH: Liver Neoplasms
Cytotoxic T cell
MESH: Animals
Replicon
MESH : Influenza A Virus, H9N2 Subtype
MESH: Phylogeny
MESH: Treatment Outcome
0303 health sciences
MESH : Peptides
MESH: Peptides
Liver Neoplasms
MESH : Reverse Transcriptase Polymerase Chain Reaction
Flow Cytometry
MESH : Influenza in Birds
3. Good health
MESH : Influenza A virus
MESH : Immunotherapy
Oncology
MESH: RNA, Viral
MESH : Animal Migration
Immunotherapy
Carcinoma, Hepatocellular
T cell
Immunology
MESH: Replicon
03 medical and health sciences
MESH: Species Specificity
MESH: Animals, Wild
MESH : Birds
MESH: Prevalence
Histocompatibility Antigens Class I
Mengovirus
RNA
MESH : Disease Models, Animal
Mice, Inbred C57BL
MESH: Disease Models, Animal
Peptides
MESH: Female
Cancer Research
MESH : Liver Neoplasms
MESH : Mengovirus
MESH: Histocompatibility Antigens Class I
MESH: Reverse Transcriptase Polymerase Chain Reaction
Immunology and Allergy
MESH : Female
MESH: Carcinoma, Hepatocellular
MESH : Animals, Wild
MESH : Cloaca
biology
MESH : Cancer Vaccines
MESH: Animal Migration
medicine.anatomical_structure
Treatment Outcome
MESH: Birds
MESH: Sentinel Surveillance
RNA, Viral
MESH : Histocompatibility Antigens Class I
MESH : Replicon
MESH : Carcinoma, Hepatocellular
MESH : Sentinel Surveillance
MESH : Flow Cytometry
MESH : Male
MESH: Influenza A virus
MESH : Mice, Inbred C57BL
MESH : Treatment Outcome
Cancer Vaccines
MESH: Influenza in Birds
MESH: Mice, Inbred C57BL
MESH : Mice
medicine
MESH : Species Specificity
MESH : RNA, Viral
Animals
MESH : France
MESH: Mice
030304 developmental biology
MESH : Phylogeny
biology.organism_classification
MESH: Male
MESH: Cloaca
MESH: Influenza A Virus, H9N2 Subtype
MESH: France
Disease Models, Animal
MESH : Animals
CD8
MESH: Mengovirus
030215 immunology
Subjects
Details
- Language :
- English
- ISSN :
- 03407004 and 14320851
- Database :
- OpenAIRE
- Journal :
- Cancer Immunology, Immunotherapy, Cancer Immunology, Immunotherapy, Springer Verlag, 2008, 57 (8), pp.1161-71. ⟨10.1007/s00262-007-0448-3⟩, Cancer Immunology, Immunotherapy, 2008, 57 (8), pp.1161-71. ⟨10.1007/s00262-007-0448-3⟩, Cancer Immunology and Immunotherapy, Cancer Immunology and Immunotherapy, 2008, 57 (8), pp.1161-71. 〈10.1007/s00262-007-0448-3〉
- Accession number :
- edsair.doi.dedup.....89120fc82a737f852c1cc9cd5015a0d5
- Full Text :
- https://doi.org/10.1007/s00262-007-0448-3⟩